WHWK Insider Trading
Insider Ownership Percentage: 49.90%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $2,584,564.00
Whitehawk Therapeutics Share Price & Price History
Current Price: $4.03
Price Change: ▼ Price Decrease of -0.14 (-3.36%)
As of 04/24/2026 05:00 PM ET
Whitehawk Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/16/2026 | Scott M Giacobello | CFO | Sell | 141,600 | $4.13 | $584,808.00 | 295,224 | |
| 4/15/2026 | Scott M Giacobello | CFO | Sell | 77,000 | $3.86 | $297,220.00 | 436,824 | |
| 4/14/2026 | Bryan Ball | Insider | Sell | 92,460 | $3.64 | $336,554.40 | 397,106 | |
| 4/13/2026 | Bryan Ball | Insider | Sell | 26,389 | $3.46 | $91,305.94 | 489,566 | |
| 4/10/2026 | Bryan Ball | Insider | Sell | 6,596 | $3.43 | $22,624.28 | 515,955 | |
| 4/9/2026 | Bryan Ball | Insider | Sell | 50,000 | $3.57 | $178,500.00 | 522,551 | |
| 4/9/2026 | David James Lennon | CEO | Sell | 14,500 | $3.38 | $49,010.00 | 518,622 | |
| 4/8/2026 | David James Lennon | CEO | Sell | 63,945 | $3.40 | $217,413.00 | 533,122 | |
| 4/7/2026 | David James Lennon | CEO | Sell | 94,087 | $3.43 | $322,718.41 | 597,067 | |
| 4/6/2026 | David James Lennon | CEO | Sell | 102,395 | $3.51 | $359,406.45 | 691,154 | |
| 4/2/2026 | David James Lennon | CEO | Sell | 26,858 | $3.48 | $93,465.84 | 793,549 | |
| 3/2/2026 | Bryan Ball | Insider | Sell | 1,834 | $3.31 | $6,070.54 | 206,019 | |
| 3/2/2026 | David James Lennon | CEO | Sell | 5,100 | $3.31 | $16,881.00 | 44,579 | |
| 3/2/2026 | Scott M Giacobello | CFO | Sell | 2,594 | $3.31 | $8,586.14 | 28,100 | |
Whitehawk Therapeutics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 2/18/2026 | KVP Capital Advisors LP | 2,165,997 | $5.24M | 5.1% | N/A | 4.596% |  |
| 2/18/2026 | XTX Topco Ltd | 15,704 | $38K | 0.0% | -20.6% | 0.033% |  |
| 2/18/2026 | Quadrature Capital Ltd | 11,447 | $28K | 0.0% | N/A | 0.024% |  |
| 2/18/2026 | Eversept Partners LP | 260,259 | $0.63M | 0.0% | N/A | 0.552% |  |
| 2/17/2026 | ADAR1 Capital Management LLC | 77,593 | $0.19M | 0.0% | N/A | 0.165% |  |
| 2/13/2026 | Marshall Wace LLP | 67,959 | $0.16M | 0.0% | N/A | 0.144% |  |
| 2/13/2026 | State Street Corp | 145,537 | $0.35M | 0.0% | +111.7% | 0.309% |  |
| 2/12/2026 | Jane Street Group LLC | 69,931 | $0.17M | 0.0% | +177.3% | 0.148% |  |
| 2/12/2026 | Renaissance Technologies LLC | 440,722 | $1.07M | 0.0% | -3.7% | 0.935% |  |
| 2/12/2026 | Dimensional Fund Advisors LP | 28,641 | $69K | 0.0% | -35.1% | 0.061% |  |
| 2/9/2026 | Geode Capital Management LLC | 425,440 | $1.03M | 0.0% | +11.4% | 0.903% |  |
| 11/17/2025 | Acorn Capital Advisors LLC | 1,139,363 | $2.17M | 1.1% | N/A | 2.418% |  |
| 11/17/2025 | Yu Fan | 2,070,000 | $3.93M | 5.1% | N/A | 4.392% |  |
| 11/17/2025 | Citadel Advisors LLC | 140,220 | $0.27M | 0.0% | N/A | 0.298% |  |
| 11/17/2025 | Ally Bridge Group NY LLC | 817,939 | $1.55M | 0.9% | N/A | 1.735% |  |
| 11/17/2025 | ABG Innovation Capital Partners III GP Ltd | 26,666 | $51K | 100.0% | N/A | 0.057% |  |
| 11/14/2025 | Orbimed Advisors LLC | 4,166,000 | $7.92M | 0.2% | N/A | 8.840% |  |
| 11/14/2025 | Acuta Capital Partners LLC | 3,410,402 | $6.48M | 6.7% | N/A | 7.236% |  |
| 11/14/2025 | Bridgeway Capital Management LLC | 215,284 | $0.41M | 0.0% | N/A | 0.457% |  |
| 11/14/2025 | Squarepoint Ops LLC | 83,660 | $0.16M | 0.0% | N/A | 0.178% |  |
| 11/14/2025 | Suvretta Capital Management LLC | 3,700,000 | $7.03M | 0.2% | N/A | 7.851% |  |
| 11/14/2025 | Avoro Capital Advisors LLC | 2,849,402 | $5.41M | 0.1% | N/A | 6.046% |  |
| 11/12/2025 | Dimensional Fund Advisors LP | 44,115 | $84K | 0.0% | N/A | 0.094% |  |
| 11/10/2025 | Peapod Lane Capital LLC | 303,585 | $0.58M | 0.5% | N/A | 0.644% |  |
| 11/7/2025 | Vanguard Group Inc. | 1,342,907 | $2.55M | 0.0% | N/A | 2.849% |  |
Data available starting January 2016
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Read More on Whitehawk Therapeutics
Volume
134,384 shs
Average Volume
227,878 shs
Market Capitalization
$190.20 million
P/E Ratio
8.57
Dividend Yield
N/A
Beta
0.57
Who are the company insiders with the largest holdings of Whitehawk Therapeutics?